Status:
COMPLETED
Observationa Study is a Prospective and Multi-institutional Observational Study.
Lead Sponsor:
Jeil Pharmaceutical Co., Ltd.
Conditions:
Erosive Reflux Disease
Heartburn
Eligibility:
All Genders
19+ years
Brief Summary
This observational study is a prospective, multi-institutional non intervention study to examine the prescription patterns, corresponding treatment effects and safety in routine clinical practice for ...
Detailed Description
The present observational study is designed to check effect and safety for patients who have been prescribed JAQBO for the treatment of erosive gastroesophageal reflux disease.
Eligibility Criteria
Inclusion
- An adult over 19 years of age
- A person who voluntarily provides written informed consent
Exclusion
- A pregnant woman or a nursing woman
- A person who is deemed unsuitable for the subject of the study
Key Trial Info
Start Date :
November 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 23 2025
Estimated Enrollment :
5536 Patients enrolled
Trial Details
Trial ID
NCT06952855
Start Date
November 1 2024
End Date
April 23 2025
Last Update
May 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Goodbreath Medical Center
Seoul, Gyeonggi-do, South Korea, 15865